Richard Lafayette, MD
Nephrology · Stanford, CANPI 1922141951
Payments from drug & device makers
Across 564 payments — averaging $5386.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$878K
- Beigene, Ltd.$770K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$290K
- Travere Therapeutics, Inc.$245K
- AstraZeneca$166K
- Beone Medicines Ltd.$125K
- plus $564K from 21 others
Across 26 payments — averaging $4573.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$69K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$33K
- Omeros Corporation$6K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Amgen$5K
- Novartis Pharma AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 62 | $877,664 |
| Beigene, Ltd. | 20 | $770,164 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 28 | $289,939 |
| Travere Therapeutics, Inc. | 161 | $245,331 |
| AstraZeneca | 62 | $165,719 |
| Beone Medicines Ltd. | 7 | $125,480 |
| Pfizer | 23 | $115,727 |
| Otsuka Pharmaceutical Co., Ltd. | 24 | $89,202 |
| Calliditas Therapeutics US Inc. | 39 | $81,748 |
| Genentech, Inc. | 9 | $59,319 |
| Mallinckrodt Enterprises LLC | 14 | $35,816 |
| Biocryst Pharmaceuticals, Inc. | 16 | $32,732 |
| Apellis Pharmaceuticals, Inc. | 9 | $23,995 |
| GSK | 3 | $22,060 |
| Vertex | 20 | $21,099 |
| Amgen | 9 | $18,158 |
| Mallinckrodt Hospital Products Inc. | 14 | $16,048 |
| Bioverativ Therapeutics Inc. | 5 | $12,101 |
| Beigene USA, Inc. | 12 | $7,180 |
| Aurinia Pharma U.S., Inc. | 9 | $6,964 |
| Omeros Corporation | 6 | $5,318 |
| ANI Pharmaceuticals, Inc. | 4 | $5,077 |
| Otsuka America Pharmaceutical, Inc. | 2 | $4,525 |
| Biogen | 2 | $3,500 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $1,830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,280 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
How this compares
$3,037,998 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Stanford
- Glenn ChertowStanford$2.2M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Anant DesaiGranada Hills$2.9M
- George Faddala Mesa$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.